

## Benralizumab (anti-IL5RA )

Cat. No.:	HY-P9923A
CAS No.:	1044511-01-4
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor  $\alpha$  (IL-5R $\alpha$ )-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study <sup>[1][2]</sup>.

### REFERENCES

[1]. Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5(3):00009-2019. Published 2019 Sep 25.

[2]. Kolbeck R, et al. MEDI-563, a humanized anti-IL-5receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicityfunction. J Allergy Clin Immunol. 2010;125(6):1344-1353.e2.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA